Contralateral risk-reducing mastectomy

What the operation is

A contralateral risk-reducing mastectomy — sometimes shortened to CRRM — is the surgical removal of the healthy, unaffected breast in a patient who has been treated, or is being treated, for a cancer in the other breast. The aim is to reduce the risk of a future primary cancer developing in that second breast.

It is a different conversation from risk-reducing mastectomy when there is no prior cancer, even though the operation itself is the same. The decision depends on your first cancer, your genetic and family-history picture, the treatment plan for that cancer, and what matters most to you after a recent diagnosis.

This page is for patients who are considering a contralateral mastectomy at the same time as their cancer surgery (a bilateral mastectomy, with one side cancer surgery and the other side risk-reducing), or as a separate operation later in the cancer pathway.

When it is considered

Contralateral risk-reducing mastectomy is most clearly justified — and most often recommended — when the patient carries a substantially raised risk of a future cancer in the other breast:

Confirmed BRCA1, BRCA2, or PALB2 mutation — the lifetime risk of a second primary cancer in the other breast is substantially raised, and surgical risk reduction in the unaffected breast is supported by good evidence.
TP53 (Li-Fraumeni) mutation or another strongly inherited cancer gene.
Very strong family history of breast or ovarian cancer that meets the threshold for high-risk classification, even without an identified gene.

How much CRRM reduces the chance of a new cancer in the other breast depends on the underlying risk. For BRCA1 and BRCA2 carriers, surgery removes about 90–95% of the at-risk tissue and is expected to give a similar reduction in future breast cancer risk (NCI 2024; ABS 2017). The evidence in PALB2, TP53 (Li-Fraumeni) and strong family history without a confirmed gene is less mature; the same magnitude of reduction is expected biologically, but the published evidence is smaller and the size of benefit is less certain (NHS Genomics Education Programme, PALB2 Knowledge Hub, 2024).

When it is a more open conversation

Outside of the high-risk genetic groups, the conversation is more nuanced. Many patients with a primary breast cancer ask about removing the other breast. In plain terms:

Average-risk patients with a unilateral, treated primary cancer have a future risk of cancer in the other breast that is similar to or slightly higher than the population risk — typically in the order of 0.5–1% per year, depending on the first cancer and on hormonal treatment.
Modern breast surveillance (annual mammography, sometimes with MRI) catches most contralateral cancers at an early, treatable stage.
Endocrine treatment (such as tamoxifen or an aromatase inhibitor like anastrozole) for the original cancer reduces the chance of a new cancer in the other breast by roughly 40–50%. The protection continues for at least 5–10 years after the medication is stopped (EBCTCG, Lancet 2011).

For patients without a high-risk genetic factor, the evidence does not show that removing the healthy breast helps you live longer. Most studies, including a Cochrane review (2018) and the ABS UK position statement (2017), find no overall survival benefit from contralateral risk-reducing mastectomy in this group. This is because the outlook from the original cancer is mainly set by its own biology and treatment, and most second cancers in the other breast are picked up early enough by surveillance to be treated successfully. CRRM still has a role for some patients in this group — for symmetry after a unilateral mastectomy, for reduced anxiety, or for simpler follow-up — but not as a way to improve survival This does not mean the operation has no role in this group — for some patients the psychological benefit (reduced anxiety about the other breast, simpler imaging follow-up, symmetry after a unilateral mastectomy) is itself a meaningful reason. But it is a different conversation from the high-risk genetic situation.

The honest framing is something like: for high-risk gene carriers, CRRM is recommended on risk grounds; for others, it is an option that some patients choose for reasons that go beyond strict survival benefit, and choosing not to have it is also entirely reasonable.

Reasons patients choose CRRM

Reasons commonly cited by patients who choose contralateral mastectomy include one or more of:

A confirmed high-risk genetic mutation identified during the cancer pathway.
A strong family history that, although not meeting strict gene-mutation criteria, raises concern.
Symmetry after a unilateral mastectomy — particularly when reconstruction is part of the plan, bilateral mastectomy with bilateral reconstruction often gives a more symmetric long-term result than a unilateral mastectomy alone.
Anxiety about the other breast — for some patients, the worry of a future second cancer is a meaningful daily burden, and surgical risk reduction relieves it in a way that surveillance does not.
Avoiding future imaging burden — annual mammography and MRI for many years is a real commitment; some patients find it preferable to remove the unaffected breast and step out of that surveillance pathway.
A previous history of difficult biopsies or recall — patients who have had repeated work-up of the contralateral breast for benign findings sometimes prefer mastectomy to ongoing investigation.

None of these is, on its own, a “right” reason. They are real considerations that patients weigh in the context of a cancer diagnosis, and a good consultation surfaces them rather than dismissing them.

Reasons patients choose not to have CRRM

Equally legitimate reasons to decline contralateral mastectomy:

No identified high-risk gene — for many patients, the survival case is not strong, and the risks of additional surgery are real.
Wish to preserve normal breast tissue and sensation on the unaffected side.
Concerns about a longer recovery — bilateral surgery is more demanding than unilateral, particularly when combined with reconstruction.
Not wanting to make further surgical decisions during treatment — the cancer pathway itself is a lot to navigate; some patients prefer to focus on the first cancer treatment and revisit the contralateral question later, if at all.
Concerns about implant or reconstruction issues on a healthy breast — for patients having implant-based reconstruction on the cancer side, accepting the same on the healthy side means accepting the same long-term implant considerations bilaterally.

The decision can also be deferred — many patients have unilateral surgery for the cancer and revisit contralateral mastectomy as a separate decision months or years later. The option does not disappear after the primary surgery.

Timing — at the same time, or later?

Two paths:

Same-operation bilateral mastectomy

CRRM is performed at the same operation as the cancer mastectomy, with bilateral reconstruction (where chosen). This has practical advantages:

A single recovery rather than two.
Symmetric reconstruction from day one — easier to match two newly reconstructed breasts than to match a reconstructed breast to an unoperated breast later.
A single anaesthetic.

Disadvantages: a longer single operation, more demanding recovery in the immediate post-operative period, and the decision is made at a time when the patient is also processing the cancer diagnosis.

Delayed CRRM

The cancer side is treated first; the contralateral mastectomy is performed as a separate operation months or years later. This has different advantages:

The decision is made at a calmer time, after cancer treatment is complete.
Patients who have lived with surveillance for a year or two have a clearer sense of how much the worry of the other breast is affecting daily life.
Adjuvant treatments (chemotherapy, radiotherapy, hormone therapy) are completed without complicating reconstruction on the unaffected side.

Disadvantages: a second recovery; a period of mismatch between the reconstructed and unaffected breast; the additional surgery does not benefit from the same operation slot as the cancer surgery.

There is no single right answer. The choice between same-operation and delayed CRRM is individual.

What the operation involves

The contralateral mastectomy itself is the same operation as a mastectomy on the cancer side, with the same options:

Skin-sparing mastectomy — preserves the breast skin envelope, removes the nipple. Used when immediate reconstruction is part of the plan.
Nipple-sparing mastectomy — preserves both the skin envelope and the nipple-areolar complex. Often suitable for the contralateral healthy breast where there is no concern about the nipple being involved by cancer.
Simple mastectomy — removes all breast tissue, skin, and nipple. Used when reconstruction is not chosen.

Reconstruction on the healthy side is usually planned to match what is being done on the cancer side — implant-based, autologous, or aesthetic flat closure bilaterally. The reconstruction trade-offs are described on the reconstruction pillar page and in the dedicated procedure pages.

Sentinel lymph node biopsy is not performed on the contralateral side, because there is no diagnosed cancer to drain. (If unexpected cancer is found in the contralateral mastectomy specimen — which happens in around 1–2% of cases — sentinel lymph node biopsy may be done at a second operation, depending on the cancer’s characteristics.)

Recovery

For same-operation bilateral mastectomy with reconstruction, recovery is similar to but more demanding than unilateral surgery:

First two weeks — the bilateral nature of the operation means everyday tasks (dressing, washing, lifting) are more dependent on help in the first 1–2 weeks. Drains in place on both sides.
Weeks 2–6 — progressive mobilisation with physiotherapy on both sides, drains usually out, return to driving around 3–4 weeks. Most patients with desk-based work return at 4–6 weeks.
Three months — most physical activity resumed for implant-based reconstruction; longer for autologous reconstruction.
One year — most patients consider themselves “back to normal”, with both reconstructed breasts having settled into their final shape.

For delayed CRRM as a unilateral operation a year or two after the cancer surgery, recovery is similar to a unilateral mastectomy with reconstruction.

Common questions The questions patients ask first

Will having a contralateral mastectomy improve my chance of cure from the original cancer?

For most patients, no. The recurrence risk from the original cancer is determined by its biology and how it has been treated; removing the other breast does not change that risk. CRRM reduces the risk of a new, separate cancer developing in the other breast — a different question from cure of the first cancer. For high-risk gene carriers, that distinction matters because the risk of a new contralateral cancer is high; for others, the original cancer’s biology and adjuvant treatment do most of the work.

What is the chance of a second cancer developing in the other breast?

For an average-risk patient with a unilateral primary cancer treated with surgery and standard adjuvant therapy, the chance of a new cancer in the other breast is typically about 0.4–0.5% per year, lower again on tamoxifen or an aromatase inhibitor. For BRCA1/BRCA2 carriers who do not have contralateral surgery, the 25-year cumulative risk is around 30–45%, with the higher end seen in carriers diagnosed under age 40 (Kuchenbaecker, JAMA 2017).

Will it affect my treatment plan for the original cancer?

Usually not in any major way. Adjuvant chemotherapy, radiotherapy, and hormone therapy are decided by the original cancer’s biology, not by what is done on the contralateral side. Bilateral surgery occasionally delays the start of adjuvant treatment by a small margin because the recovery is longer; this is discussed at MDT.

What if cancer is found in the supposedly healthy breast?

Around 1–5% of contralateral mastectomy specimens contain an unexpected, previously undetected cancer or DCIS, with the higher end seen in series that include strong family-history or BRCA cohorts (ABS / Manchester guidelines, 2015). If that happens, the case is reviewed at MDT and any extra treatment (sentinel lymph node biopsy, hormone therapy, occasionally chemotherapy) is decided then. The reconstruction is not usually affected.

Will my insurance cover it?

Funding depends on your insurer’s policy. Most major UK insurers will consider CRRM where there is a documented high-risk genetic result or a family history meeting the agreed threshold, and our practice administrator (PA) can help with the pre-authorisation paperwork. CRRM in the absence of these criteria is sometimes — but not always — funded; we will tell you what your insurer’s written response is before the operation is booked.

Should I have it now or wait?

There is no clinical urgency for CRRM unless a high-risk genetic result has been identified. For most patients, either same-operation or delayed CRRM is reasonable. Patients who are unsure often benefit from completing cancer treatment first and revisiting the question once the most acute period of treatment is behind them.

Can I have surgery on one side first and the other later?

Yes. Many patients have unilateral cancer surgery and revisit the contralateral question later. This is sometimes called “staged” surgery. The cosmetic match between a reconstructed and a delayed-mastectomy breast is sometimes a small consideration but is usually addressed well at the second operation.